SCHEMBL4346870

SCHEMBL4346870

CS(=O)(=O)Nc1cccc(-c2cccc(N)c2O)c1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 1/20 0.54
CHUK O15111 1/20 0.54
HSD17B1 P14061 3/20 0.52
HSD17B2 P37059 3/20 0.52
KIF11 P52732 1/20 0.51
PTK2 Q05397 1/20 0.49
BRD4 O60885 5/20 0.49
HSP90AA1 P07900 2/20 0.48
HSP90AB1 P08238 2/20 0.48
CYP1A2 P05177 2/20 0.47
CYP3A4 P08684 2/20 0.47
CYP2D6 P10635 2/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
KDM1A O60341 1/20 0.47
ALDH1A1 P00352 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
CLK4 Q9HAZ1 1/20 0.46
HTT P42858 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2403403 0.83 CA2 (0.52) IKBKBCHUKHSD17B1HSD17B2KIF11
SCHEMBL4344095 0.79 HSD17B1 (0.48) IKBKBCHUKHSD17B1HSD17B2KIF11
SCHEMBL2408036 0.77 SCN9A (0.46)
SCHEMBL31610096 0.76 CHUK (0.70) IKBKBCHUKHSD17B1HSD17B2KIF11
SCHEMBL16759969 0.76 BRD4 (0.60) IKBKBCHUKHSD17B1HSD17B2KIF11
SCHEMBL23479682 0.75 BRD4 (0.57) HSD17B1HSD17B2KIF11BRD4CYP1A2
Hydrochloric Acid SCHEMBL28038531 0.75 IKBKB (0.55) IKBKBCHUKHSD17B1HSD17B2KIF11
SCHEMBL29788210 0.75 BRD4 (0.56) IKBKBCHUKHSD17B1HSD17B2KIF11
SCHEMBL6851259 0.74 PGAM1 (0.48) IKBKBCHUKKDM1A
SCHEMBL30422612 0.74 IKBKB (0.60) IKBKBCHUKHSD17B1HSD17B2KIF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130078213-A1 THROMBOPOIETIN MIMETICS GLAXOSMITHKLINE LLC 2013-03-28 US disclosed
EP-1889838-B1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORP (US) 2009-10-14 EP disclosed
EP-1889838-A1 Thrombopoietin mimetics SmithKline Beecham Corporation (US) 2008-02-20 EP disclosed
EP-1864981-A1 Thrombopoietin mimetics SmithKline Beecham Corporation (US) 2007-12-12 EP disclosed
US-20070129338-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION 2007-06-07 US disclosed
US-20040019190-A1 Thrombopoietin mimetics NOVARTIS AG (CH) 2004-01-29 US disclosed
EP-1294378-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2004-01-28 EP disclosed
EP-1294378-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-26 EP disclosed
WO-2001089457-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2001-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129338-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK IKBKB 818/4885CHUK 2545/4885HSD17B1 1729/4885
US-20130078213-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK IKBKB 818/4885CHUK 2545/4885HSD17B1 1729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.